says company founder Marko Lehes. “We know we can reach our goals here: To make our diagnostics fast, easy, scalable – and accessible to as many people as possible.”
Case Study
Case Study
Rapid testing methods are becoming increasingly vital for the accurate identification and treatment of diseases, including epidemic prevention. Selfdiagnostics Deutschland GmbH is revolutionizing this field of diagnostics with its innovative approaches and technologies.
Founded in Leipzig in 2011, the R&D company develops and manufactures products which can detect a variety of different illnesses. Their team of scientists and engineers created a platform of single-use multiplex molecular diagnostic tests for a range of infections, including COVID-19.
Medical problem-solving at this highest level requires a unique blend of know-how, infrastructure and funding. Leipzig proved itself to be an ideal location in this regard, offering the company numerous benefits:
The company established its headquarters on Leipzig’s BioCity Campus, which enables innovative Start Ups like Selfdiagnostics to mature into successful Grow Ups with wide market penetration.
says company founder Marko Lehes. “We know we can reach our goals here: To make our diagnostics fast, easy, scalable – and accessible to as many people as possible.”
Small as a credit card, the PCR testing platform combines the ease-of-use of a rapid test with the accuracy of a PCR test – with a fast turnaround. The COVID-19 Multitest e.g. delivers a reliable result with near 100% sensitivity and specificity in 45 minutes.
Selfdiagnostics Deutschland GmbH
Selfdiagnostics is an Estonian-German R&D company which develops, manufactures and sells medical devices. Its product portfolio includes diagnostic tests, inhalers and blood pressure monitors. After successfully launching a rapid diagnostic test for sexually transmitted diseases, the company is now focusing on developing RNA diagnostic products for SARS-CoV-2 and other respiratory viruses. Find out more at: selfdiagnostics.eu
The causes of intelligence impairment or epilepsy remain unexplained in more than 50 per cent of cases.
This year’s FlyPharma Europe venue, Leipzig, was chosen due to the excellent biotech and life sciences hub BIO CITY LEIPZIG
Diagnosing rare diseases so patients can receive timely treatment is a major challenge in healthcare. Saventic Health is transforming medical diagnostics by using artificial intelligence (AI) to identify rare diseases, reduce diagnosis times and expedite treatment.
Testing for infectious diseases can be a slow, complex and resource-intensive process. Intu Diagnostics is transforming the diagnostic landscape with fast, affordable and easy-to-use diagnostic solutions which anyone around the world can use to test themselves.